GlassScriptPhysician profile
Diana E Westcott
NPI 1023788007
$550.82
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $142 · 2023: $150 · 2024: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $67.90 | 2024 | Resmetirom |
| Veloxis Pharmaceuticals, INC. | $65.43 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.77 | 2022 | |
| Alexion Pharmaceuticals, INC. | $48.18 | 2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $41.41 | 2024 | |
| Astellas Pharma US INC | $33.61 | 2022-2023 | Cresemba |
| Baxter Healthcare | $33.61 | 2023 | Tisseel |
| Medtronic, INC. | $32.41 | 2024 | Signia |
| Intercept Pharmaceuticals, INC. | $32.08 | 2023-2024 | Ocaliva |
| Gilead Sciences, INC. | $30.10 | 2024 | |
| Acera Surgical, INC. | $26.53 | 2024 | Restrata Wound Matrix |
| Innovation Technologies INC | $25.84 | 2024 | Irrisept |
| Kci USA, INC. | $19.71 | 2023 | Prevena |
| Orphalan INC | $19.36 | 2024 | Cuvrior |
| Merck Sharp & Dohme LLC | $17.88 | 2023 | Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Westcott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.